Article

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms

2026-01-21

Abstract excerpt

Acute Myeloid leukemia (AML) is characterized by differentiation arrest, driving blast proliferation and abnormal blood formation. While differentiation therapy revolu-tionized acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), its extension into non-APL AML has been limited until recent targeted agents. This narrative review synthesizes preclinical and clinical evid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 6494174c-845b-5b65-846d-5f39b3b8af70
DOI: 10.20944/preprints202601.1529.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic ParadigmsDOI 10.20944/preprints202601.1529.v1Read

Differentiation therapy of myeloid leukemia: four decades of developmentSemantic proximity Read

Recent Developments in Differentiation Therapy of Acute Myeloid LeukemiaSemantic proximity Read

Advances in acute myeloid leukemia differentiation therapy: A critical reviewSemantic proximity Read

Differentiation therapy for myeloid malignancies: beyond cytotoxicity.Semantic proximity Read

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.Semantic proximity Read

Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.Semantic proximity Read

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read

Revumenib for patients with acute leukemia: a new tool for differentiation therapySemantic proximity Read

Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study.Semantic proximity Read

Acute myeloid leukemia: current progress and future directions.Semantic proximity Read

Advances in the pharmacological management of acute myeloid leukemia in adults.Semantic proximity Read